News

The company said its decision was based on evidence of tumour-inhibiting activity from early pre-clinical trials with the technology. GBM accounts for 16% of all diagnosed brain cancers

Afferent develops therapeutic candidates targeting the P2X3 receptor to treat common, poorly-managed, neurogenic conditions. The agreement gives Merck access to Afferent’s lead investigational candidate, AF-219, which is a

South African generic-drugs maker Aspen will also pay AstraZeneca royalties and about $250m in additional sales-based installments in the next two years. AstraZeneca’s anaesthetics portfolio includes five local

Lion Biotechnologies received gross proceeds of $100m, before paying the placement agents’ fees and estimated offering expenses payable by the Company. t the closing, the Company issued 9,684,000

The P2MC technology allows for the efficient, reproducible and chemically defined differentiation of pluripotent cells into skeletal muscle stem cells, also known as satellite cells. The agreement will

The Fast Track designation, established under the FDA Modernization Act of 1997, is designed to facilitate the development and expedite the review of drugs that are intended to

The MAA filing was based on data from the company’s completed phase 2 study. During the May 2016 Committee for Medicinal Products for Human Use (CHMP) meeting, the

Erenumab, which is being co-developed with Novartis, was tested at the 70 mg and 140 mg doses in a 12-week, 667-patient phase 2 study of subjects who were

Under the partnership, Ultragenyx will receive an exclusive license to one preclinical Takeda candidate in an unspecified predetermined area of use. Ultragenyx will retain an exclusive option to